-
- Vitamin D can halve the risk of a second heart attack.
-
- A personalized dosing strategy was key to the breakthrough.
-
- Researchers have tailored dosages to achieve specific blood level goals.
-
- More than half of the patients required a high dose of 5,000 IU daily.
-
- No adverse effects of the customized treatment were observed in the study.
A simple, affordable and natural vitamin could be the key to cutting the risk of a second heart attack in half. In a medical breakthrough that challenges the conventional, pharmaceutical-focused approach to heart disease, new research demonstrates the profound power of a personalized nutrition strategy. This isn’t about a one-size-fits-all pill, but about harnessing the body’s own needs to promote true healing.
The findings come from the TARGET-D clinical trial conducted by Intermountain Health in Salt Lake City. Researchers found that when patients who had recently had a heart attack were given vitamin D3 doses tailored to their specific blood levels, they saw their risk of another heart attack reduced by 52 percent. This precise target-to-treat method marks a significant departure from previous failed supplement studies.
The study, presented at the American Heart Association Scientific Sessions 2025 in New Orleans, offers a compelling new direction for preventive cardiology. The implications are global, as it is estimated that half to two-thirds of the world’s population has low vitamin D levels. What was once abundantly available through sunlight is now a common deficiency, making targeted supplementation a crucial public health conversation.
A new approach to an old problem
Observational studies have linked low vitamin D levels to poor heart health for years. Yet clinical trials that simply gave each participant a standard, low dose of vitamin D consistently failed to show any benefit. The Intermountain team hypothesized that the problem was not the vitamin itself, but the outdated dosing strategy.
“Previous clinical research on vitamin D has tested the potential impact of the same vitamin D dose for all participants without first checking their blood levels,” said Heidi T. May, Ph.D., the study’s lead researcher. “We took a different approach. We monitored each participant’s vitamin D levels at enrollment and throughout the study, and we adjusted their dose as necessary.”
How the targeted treatment worked
The trial, which ran from 2017 to 2023, followed 630 adults who had had a heart attack. Participants were randomly assigned to a standard care group or a treatment group. The treatment group did not receive a uniform pill. Instead, their vitamin D blood levels were closely monitored with the aim of achieving and maintaining levels between 40 and 80 nanograms per milliliter.
The results were striking. An overwhelming 85 percent of all participants entered the study with vitamin D deficiency below 40 ng/ml. To reach the target range, more than half of the people in the treatment group needed a starting dose of 5,000 IU vitamin D3 daily. This is more than six times the FDA’s standard daily recommendation of 800 IU, highlighting how inadequate the general guidelines are for correcting deficiencies.
During the nearly four-year follow-up, researchers carefully tracked major cardiac events. While the overall risk of a combination of events, including stroke, heart failure or death, was not significantly different, the risk of one specific, life-threatening event plummeted. The risk of another heart attack was halved for those who followed the personalized vitamin D plan.
No adverse effects were observed from the higher, tailored doses in the study, underscoring the safety of this approach when administered appropriately. This precision protocol, which included regular blood tests to prevent toxicity, provides a clear and safe blueprint for doctors.
This research powerfully illustrates that the future of medicine may not lie in inventing new synthetic drugs, but in intelligently optimizing the natural substances our bodies are designed to use. It empowers individuals with the knowledge that they can control a core aspect of their health through simple, targeted nutrition.
Heidi May and her team plan to initiate a larger clinical trial to confirm these exciting results. This next step will determine whether this personalized vitamin D strategy can also help prevent first heart attacks, potentially turning nutritional science into a frontline defense for one of the world’s biggest killers.
Sources for this article include: